James A. Bristol, Ph.D. is Chairman of the Deciphera Board of Directors. Dr. Bristol worked for 32 years in drug discovery research and preclinical development at Schering-Plough Corporation, Parke-Davis and Pfizer Inc., serving in various senior research and development roles. From 2003 until his retirement in 2007, Dr. Bristol served as Senior Vice President of Worldwide Drug Discovery Research at Pfizer Global Research & Development, where he oversaw 3,000 scientists at 7 Pfizer sites as they produced an industry leading number of drug development candidates in 11 therapeutic areas. In 2009, Dr. Bristol joined Frazier Healthcare Ventures as a Senior Advisor. He has served as director of Ignyta, Inc. since 2014 and Cadent Therapeutics, Inc. since 2011. Dr. Bristol is the author of over 100 publications, abstracts and patents, and he conducted postdoctoral research at the University of Michigan (NIH Postdoctoral Fellow) and at The Squibb Institute for Medical Research. Dr. Bristol holds a Ph.D. in organic chemistry from the University of New Hampshire and a B.S. in Chemistry from Bates College.
Patricia L. Allen joined Zafgen as Chief Financial Officer in January 2013. Ms. Allen serves as the Chair of the Audit Committee of the Deciphera Board of Directors. Ms. Allen has over 20 years of financial leadership experience in the biotechnology industry at both publicly traded and private companies. From 2011 to 2012, she provided independent consulting services to biotechnology companies in a variety of areas, including interim chief financial officer services, fundraising, deal structures, financial planning, organizational structure, investor relations and business development. Previously, from 2004 to 2011, Ms. Allen served as the Vice President of Finance, Treasurer and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., a publicly traded biotechnology company. Prior to Alnylam, Ms. Allen was at Alkermes, Inc., a publicly traded biotechnology company, most recently as the Director of Finance. Ms. Allen began her career as an auditor at Deloitte & Touche, LLP. Ms. Allen graduated summa cum laude from Bryant College with a B.S. in business administration.
Edward J. Benz, Jr., M.D. is currently the Richard and Susan Smith Distinguished Professor of Medicine, professor of Pediatrics, professor of Pathology, and faculty dean emeritus for Oncology at Harvard Medical School. From November 2000 until October 2016, Dr. Benz served as President and Chief Executive Officer of the Dana-Farber Cancer Institute, Chief Executive Officer of Dana-Farber/Partners CancerCare, Director of Dana-Farber/Harvard Cancer Center and a Trustee of Dana-Farber/Children’s Hospital Cancer Care. Prior to joining Dana-Farber, Dr. Benz was chairman of the Department of Medicine at the Johns Hopkins University School of Medicine and the Sir William Osler Professor of Medicine. Dr. Benz is also a past president of both the American Society of Hematology and the American Society of Clinical Investigation. From March 2002 to June 2016, Dr. Benz served as associate editor of the New England Journal of Medicine. He also serves on the boards of directors of
Candel Therapeutics and Knowledge to Practice, Inc., privately held companies, as well as non-profit organizations, including the MDI Biological Laboratory, Rockefeller University, Mount Desert Island Hospital, Friends of Cancer Research and the American Cancer Society. Dr. Benz is the author of over 300 books, chapters, reviews and abstracts. Dr. Benz holds an M.D. degree magna cum laude from Harvard Medical School, a M.A. Privatim degree from Yale University and an A.B. degree cum laude from Princeton University.
Frank S. Friedman currently serves as Chief Executive Officer at a privately-held finance company. Previously, Mr. Friedman worked for Deloitte Touche Tohmatsu Limited (Deloitte), a global services organization, from 1979 until his retirement from Deloitte in November 2019. During this time, Mr. Friedman served in several senior officer positions at Deloitte, including as the global Chief Operating Officer from June 2015 through June 2019. Mr. Friedman has also served as Deloitte’s US Chief Operating Officer, from June 2015 to June 2017 and Deloitte’s US Chief Financial Officer, from June 2011 through May 2016. Mr. Friedman served as interim US Chief Executive Officer from 2014 to 2015. Mr. Friedman received his Bachelor of Arts in accounting and business administration from the University of Kansas.
Steven L. Hoerter is President and CEO of Deciphera Pharmaceuticals. Prior to joining Deciphera, Mr. Hoerter was Chief Commercial Officer at Agios Pharmaceuticals, Inc. where he built and led the team responsible for the commercialization of the company’s portfolio of first-in-class medicines for oncology and rare genetic diseases. Prior to joining Agios in 2016, Mr. Hoerter was Executive Vice President and Chief Commercial Officer at Clovis Oncology, Inc. Before joining Clovis, Mr. Hoerter was General Manager and Management Center Head at Roche for the Sub-Saharan Africa and Indian Ocean Region. From 2005 to 2010, he held a variety of positions at Genentech, Inc., including serving on the senior leadership team for Genentech’s BioOncology business. Prior to that, Mr. Hoerter held commercial roles at Chiron Corporation and Eli Lilly and Company in the U.S., Europe, and Africa. Mr. Hoerter currently serves on the Board of Directors at Constellation Pharmaceuticals, a biotechnology focused on developing novel therapeutics for patients with cancers associated with abnormal gene expression and was previously a member of the Board of Directors of Ignyta, Inc., a biotechnology company focused on precision medicine in oncology, until the company’s acquisition by Roche in 2017. Mr. Hoerter received his B.A. from Bucknell University, M.B.A. from Tilburg University in the Netherlands and M.S. in management from Purdue University.
Susan L. Kelley, M.D. brings to Deciphera over 25 years of experience across all stages of oncology drug research and development. Most recently she served as Chief Medical Officer of the Multiple Myeloma Research Consortium (MMRC) where she led the strategic design and management of clinical trials conducted by leading myeloma clinical research centers in North America. Prior to the MMRC, she held positions of increasing responsibility at Bayer Healthcare Pharmaceuticals and Bayer-Schering Pharma, including Vice President, Global Clinical Development and Therapeutic Area Head – Oncology, where she led the team responsible for the development and worldwide regulatory approval of Nexavar® (sorafenib). Prior to joining Bayer, Dr. Kelley worked at Bristol-Myers Squibb in Oncology and Immunology drug development, ultimately serving as Executive Director, Oncology Clinical Research, at the Bristol-Myers Squibb Pharmaceutical Research Institute. She currently serves as a member of the Board of Directors at multiple publicly traded companies including VBL Therapeutics, Daré Bioscience, Inc., and ArQule, Inc. Dr. Kelley received her M.D. from Duke University School of Medicine. She was a Fellow in Medical Oncology and Clinical Fellow in Medicine at Dana-Farber Cancer Institute, Harvard Medical School, and a Fellow in Medical Oncology and Pharmacology at Yale University School of Medicine, where she also served as a Clinical Assistant Professor of Medicine.
John Martin is the CEO and President of Clinical Reference Laboratory. Mr. Martin has also served as President and Chief Executive Officer of CHC, Inc., the parent company of Clinical Reference Laboratory, since June 2016, in addition to serving as the Chairman of the Board of FormFox, Inc., another subsidiary of CHC, Inc., since August 2016. Prior to joining Clinical Reference Laboratory, Mr. Martin held senior executive roles with Viracor-IBT Laboratories, a clinical diagnostic laboratory specializing in infectious disease and immunology, first as its Chief Financial Officer and then as its President and Chief Executive Officer. Prior to Viracor, Mr. Martin was with George K. Baum & Company, where he served as Managing Director leading the firm’s middle market investment banking and strategic advisory practice. Mr. Martin’s career also includes 11 years in management roles with Sprint Corporation and General Electric. Mr. Martin holds a B.S. in Finance from Kansas State University.
Ron Squarer served as Chief Executive Officer and a member of the Board of Directors of Array BioPharma, Inc. (Array) from 2012 until its acquisition by Pfizer Inc. (Pfizer) in August 2019 following the successful commercial launches of both Braftovi® and Mektovi®. Before joining Array, Mr. Squarer held positions of increasing responsibility with Hospira, Inc., a global pharmaceutical and medical device company. As Senior Vice President and Chief Commercial Officer at Hospira, he was responsible for delivering $4 billion in annual revenue. Mr. Squarer joined Hospira from Mayne Pharma, where he served as Senior Vice President, Global Corporate and Business Development, when Mayne was sold to Hospira in 2007. Before Mayne Pharma, Mr. Squarer held leadership roles at both Pfizer (focused on oncology), and SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) in the U.S. and Europe. He currently serves as a member of the Board of Directors of Retrophin, Inc. Mr. Squarer earned an MBA from the Kellogg School of Management, Northwestern University, and a bachelor’s degree in biochemistry from the University of California, Berkeley.
Michael D. Taylor, Ph.D. served as President and CEO of Deciphera Pharmaceuticals from 2014 until 2019. Prior to joining Deciphera, Dr. Taylor was Chief Executive Officer of Ensemble Therapeutics, Corp., a small molecule drug discovery company, from July 2007 to October 2013. Prior to joining Ensemble, Dr. Taylor was Senior Vice President for Pfizer Inc.’s Global R&D division and served as Vice President, Drug Development at Warner-Lambert/Parke-Davis, where he led early and late-stage development projects across multiple therapeutic areas, including Lipitor® and Neurontin®. Dr. Taylor has authored or coauthored 65 manuscripts and published abstracts and is co-inventor on eight patents. Dr. Taylor holds a Ph.D. in Medicinal Chemistry from the State University of New York at Buffalo School of Pharmacy, was awarded an NIH postdoctoral fellowship in natural products synthesis and structure elucidation at the University of Pennsylvania and holds B.S. magna cum laude in chemistry from the University of South Florida.
Dennis Walsh, CPA is Senior Vice President and Chief Financial Officer of Americo Life, Inc, a privately owned life insurance company. Dennis was a partner with Walsh Washburn, LLC, a tax and finance consulting firm from 2003 to 2018. He was previously employed by Americo as Controller and Tax Director from 1997 to 2003. Mr. Walsh began his career with Touche Ross & Company, where he served in the tax department from 1988 to 1997. Mr. Walsh holds a Masters in Accounting from the University of Missouri, Kansas City as well as a BSBA in Accounting from Rockhurst University and is a Certified Public Accountant.